Expand VKTX Menu
VKTX MENU

VKTX Latest Press Releases

-- July 29, 2026 --

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update PRNewswire 4:05 PM

-- July 23, 2026 --

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors PRNewswire 7:39 AM

-- July 22, 2026 --

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 PRNewswire 4:05 PM

-- July 21, 2026 --

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm PRNewswire 4:41 PM

-- July 16, 2026 --

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm Globe Newswire 9:31 PM

-- June 24, 2026 --

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults PRNewswire 7:05 AM

-- June 11, 2026 --

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer PRNewswire 7:05 AM

-- May 21, 2026 --

Viking Therapeutics to Participate at Upcoming Investor Conferences PRNewswire 7:05 AM

-- May 13, 2026 --

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities Globe Newswire 8:30 AM

-- May 12, 2026 --

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 PRNewswire 7:05 AM

-- May 5, 2026 --

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 PRNewswire 7:05 AM

-- April 29, 2026 --

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update PRNewswire 4:05 PM

-- April 23, 2026 --

The Longevity Trade Is No Longer a Buzzword - It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial Globe Newswire 6:15 AM

-- April 22, 2026 --

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026 PRNewswire 4:35 PM

-- April 10, 2026 --

Viking Therapeutics to Participate at Upcoming Investor Conferences PRNewswire 7:30 AM

-- March 26, 2026 --

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 PRNewswire 7:05 AM
Market Data Delayed 15 Minutes